Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2008

View Archived Issues

Canakinumab demonstrates clinical benefit in patients with Muckle-Wells syndrome / News in Context

PF-03814735 doses, tolerability explored in solid tumor patients

MethylGene commences phase II MGCD-0103 trial in combination with Vidaza

Mpex initiates phase II aerosol MP-376 trial for chronic bacterial infections in CF

MediGene reports positive results from phase IIa clinical trial of RhuDex in RA

NITD and TB Alliance enter 5-year research collaboration for TB medicines

FDA approves 150 mg strength of Warner Chilcott's Doryx delayed-release tablets for acne

Melior and Pfizer sign option agreement for MLR-1023 for type 2 diabetes

European Commission approves extension of Amgen's marketing authorization for Mimpara

Bivalent cholera vaccine shows immunogenicity and protection against Vibrio cholerae infection

Pierre Fabre reports phase I results for omtriptolide in acute leukemias

Kinesin spindle protein inhibitor AZD-4877 evaluated in phase I studies at AstraZeneca

Astellas Pharma launches Lexiscan as pharmacologic stress agent in radionuclide MPI

Preclinical safety studies of MT-203 in inflammatory and autoimmune diseases begin

PAION completes acquisition of CeNeS

Protherics initiates enrollment in phase IIa study of angiotensin therapeutic vaccine

GPC Biotech initiates phase II trial of satraplatin in combination with prednisone in HRPC

FDA approves Sirion's NDA for Durezol in postoperative ocular inflammation and pain

New agents for treatment of HCV infection described in recent Tibotec and Arrow patents

Alkermes initiates phase III Vivitrol study for opioid dependence

Recent patents describe novel analgesic agents

Ardea reports additional positive phase IIa results for RDEA-806 in HIV

Phase III data show tasimelteon significantly improves sleep in insomnia

Avalon nominates lead clinical development candidate AVN-316

Recent Pharmacopeia patent discloses new JAK3 inhibitors

New data reported for Qnexa in high cardiovascular risk type 2 diabetics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.